focus -WSS

focus

author：explore 2025-10-02 18:06:00 - browse：57

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： FTC loses bid to block Novant's North Carolina hospital merger

WSS

How CO2 helps viruses stay alive longer in the air

FDA approves Moderna’s RSV vaccine, its second licensed product

The most pressing bird flu mysteries scientists want answered

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

A public scorecard can help hold safety

Elevance PBM president out as customers face prescription chaos

explore

focus

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Congress needs to close a vaccine

Apple is now the first public company to be valued at $3 trillion

Congress needs to close a vaccine

ChatGPT in medicine: STAT answers readers' burning questions

Google and Epic fight stronger regulation of AI in health care

Novavax promises a turnaround & Lilly roils the obesity market

Eli Lilly’s Zepbound improved liver scarring in mid

Medical records are filled with copy

Finland to offer bird flu vaccine to select groups of people, a possible global first

entertainment

Startup Neumora takes a novel depression drug to Phase 3

FDA approves Moderna’s RSV vaccine, its second licensed product

Group opposing PBM reform sets lobbying record

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Medicare to cover more brain scans for Alzheimer’s patients

WHO calls for emergency meeting on new China virus, as cases spread

focus

Wikipedia

hotspot

focus